Enveric Biosciences e sebetsa le Univesithi ea Calgary's Hotchkiss Brain Institute, setsi se etelletseng pele sa thuto ea methapo ea kutlo, Setsing sa Bongaka sa Cumming se Calgary, Canada se ikemiselitseng ho nts'etsapele lipatlisiso le thuto ea boko le bophelo ba kelello, ho theha teko e matla ea bongaka. EVM-101 bakeng sa phekolo ea Matšoenyeho a amanang le Kankere.
Hoo e ka bang karolo ea 50 lekholong ea bakuli ba mofetše ba tlaleha maemo a bophelo ba batho ba nang le khatello ea maikutlo, khatello ea maikutlo, khatello ea maikutlo, khatello ea maikutlo le maemo a fokotsehileng a bophelo. Hoo e ka bang karolo ea 40 lekholong ea bakuli ba mofetše ba kopana le maemo a ho feto-fetoha ha maikutlo a hlokang phekolo. CRD ke tlhoko ea bohlokoa ea bongaka e sa fihlelleheng e se nang tumello ea hajoale ea lipharmacotherapies le tlhoko e potlakileng ea ho ntlafatsa maemo a hajoale a tlhokomelo ho bakuli ba nang le mofetše.
Teko ea kliniki, e lebelletsoeng ho qala hamorao selemong sena, ea EVM-101, phekolo ea psychedelic ea moloko oa pele, bakeng sa CRD e tla tsamaisoa ke mofuputsi oa HBI, Dr. Valerie Taylor, Hlooho ea Lefapha la Psychiatry, Calgary, Canada.
"Re thabetse ho sebelisana 'moho le Enveric ho ithuta meriana ea moloko o latelang eo re tšepang hore e tla thusa batho ho sebetsana le mathata a bophelo bo botle ba kelello a ho hlahlojoa ke mofetše. Mosebetsi ona o tla re lumella ho bokella lisebelisoa tsa rona tse kopantsoeng ho etsa lipatlisiso likhetho bakeng sa bakuli ba kankere ba phelang le CRD, "ho bolela Dr. Valerie Taylor.
Boithuto ba EVM-101 bo tla lekola ka kotloloho likarolo tsa mantlha tsa CRD tse amehileng haholo le tse khonang ho ntlafatsoa kamora kalafo e thehiloeng ho psilocybin.
"Ka litekanyetso tse ntseng li eketseha tsa mofetše le maloetse a amanang le eona a kelello a 'nileng a nkoa a le tlaase le a sa hlahlojoang ho fihlela morao tjena, re sebetsa ka thata ho hlahisa mekhoa e mecha ea phekolo e thusang bakuli ba kankere ba nang le CRD" ho boletse Dr. Bob Dagher, Ofisiri e ka Sehloohong ea Bongaka ea Enveric. Tšebelisano ea rona le sehlopha sa lipatlisiso Univesithing ea Calgary's Hotchkiss Brain Institute le IMPACT Clinical Trial Accelerator e tla re thusa ho bonts'a melemo e ka bang teng ea liphekolo tsena tse ncha le ho etsa hore li rekisoe kapele kamoo ho ka khonehang.
Tlhahiso ea taolo ho Health Canada e lebelletsoe ho phetheloa haufinyane. Ngoliso ea bakuli tekong ea tleliniki e lebelletsoe ho qala morao ho 2022 kapa mathoasong a 2023. Moralo oa boithuto o tla sebelisa liphekolo tse tsepamisitsoeng tsa kelello le tsa kelello bakeng sa bakuli ba mofetše ba nang le CRD. Bakuli ba tla fumana tekanyo e le 'ngoe ea molomo ea EVM-101 sebakeng se tšehetsang ka psychotherapy ho ntlafatsa liphello.
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- Enveric Biosciences e sebetsa le Univesithi ea Calgary's Hotchkiss Brain Institute, setsi se etelletseng pele sa thuto ea methapo ea kutlo, Setsing sa Bongaka sa Cumming se Calgary, Canada se ikemiselitseng ho nts'etsapele lipatlisiso le thuto ea boko le bophelo ba kelello, ho theha teko e matla ea bongaka. EVM-101 bakeng sa phekolo ea Matšoenyeho a amanang le Kankere.
- “Our collaboration with the research team at the University of Calgary’s Hotchkiss Brain Institute and IMPACT Clinical Trial Accelerator will help us to demonstrate the potential benefits of these novel treatments and get them to market as quickly as possible.
- CRD is a significant unmet medical need with no current regulatory approval of pharmacotherapies and an urgent need to optimize the current standard of care for patients with cancer.
